Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.34 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4945475 | 0.86 | AURKA (0.92) | AURKAAURKBGSK3BCHEK1SRC | |
| SCHEMBL4133178 | 0.84 | AURKA (0.73) | AURKAAURKBGSK3BCHEK1SRC | |
| SCHEMBL4895191 | 0.83 | ALDH1A1 (0.47) | AURKAAURKBALDH1A1MAPTGSK3B | |
| SCHEMBL4143677 | 0.82 | AURKA (0.73) | AURKAAURKBALDH1A1GSK3BCHEK1 | |
| SCHEMBL4138252 | 0.82 | AURKA (0.73) | AURKAAURKBGSK3BCHEK1SRC | |
| SCHEMBL4140608 | 0.81 | AURKA (0.61) | AURKAAURKBALDH1A1MAPTGSK3B | |
| SCHEMBL4143663 | 0.81 | AURKA (0.71) | AURKAAURKBALDH1A1GSK3BCHEK1 | |
| SCHEMBL4130802 | 0.81 | AURKA (0.61) | AURKAAURKBMAPTLMNATP53 | |
| SCHEMBL4138011 | 0.81 | AURKA (0.61) | AURKAAURKBALDH1A1MAPTLMNA | |
| SCHEMBL4134941 | 0.81 | AURKA (0.58) | AURKAAURKBKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143375-A1 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | claimed |
| US-20150238505-A1 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS | ALKERMES PHARMA IRELAND LTD (IE) | 2015-08-27 | — | — | US | disclosed |
| US-20130309310-A1 | Injectable Nanoparticulate Olanzapine Formulations | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-11-21 | — | — | US | disclosed |
| US-20120315336-A1 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20090155331-A1 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2009-06-18 | — | — | US | disclosed |
| US-20090143375-A1 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| EP-1966213-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068465-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309310-A1 | Injectable Nanoparticulate Olanzapine Formulations | HTR3B, HTR1A, HTR1B | AURKA 1985/4885AURKB 1515/4885ALDH1A1 1756/4885 |
| US-20150238505-A1 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS | HTR3B, HTR1A, HTR1B | AURKA 1985/4885AURKB 1515/4885ALDH1A1 1756/4885 |
| US-20090143375-A1 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents | AAAS, CYP3A5, BRCA1 | AURKA 2294/4885AURKB 2649/4885ALDH1A1 898/4885 |
| US-20090155331-A1 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS | HTR3B, HTR1A, HTR1B | AURKA 1985/4885AURKB 1515/4885ALDH1A1 1756/4885 |
| US-20120315336-A1 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS | HTR3B, HTR1A, HTR1B | AURKA 1985/4885AURKB 1515/4885ALDH1A1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.